z-logo
open-access-imgOpen Access
<p>The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients</p>
Author(s) -
Wolfgang Miesbach,
Robert Klamroth
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s239810
Subject(s) - haemophilia , medicine , factor ix , anxiety , genetic enhancement , haemophilia b , clinical trial , physical therapy , haemophilia a , pediatrics , psychiatry , gene , biochemistry , chemistry
The phase ½ hemophilia B clinical trial (AMT-060) demonstrated stable endogenous FIX levels after 3.5 years (mean FIX activity between 5.1% and 7.5%) with continued reductions in annualized bleeds to near zero with the higher dose, and a 78-96% reduction by year in exogenous FIX use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here